CORONAVIRUS
Volunteers participate in a coronavirus vaccine trial at an American company in Melbourne, Australia, Tuesday, May 26.
The potential vaccine, NVX-CoV2373, is being developed by the American biotech company Novavax. It started working on the drug in January when the COVID-19 outbreak began in China. It aims to boost the body’s immune response and stimulate high levels of neutralizing antibodies.
If the vaccine works, researchers hope 100 million doses can be made by the end of this year and 1.5 billion next year.
It is a global race potentially worth billions of dollars to those who can find a safe and reliable treatment for a virus that has killed almost 350,000 people around the world.
